Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 281807
IPSCIO Record ID: 28656
Sumatriptan is a headache medicine. It is believed to work by narrowing the blood vessels around the brain.
IPSCIO Record ID: 214112
The competitive market for Cambia is to be the triptan class of drugs or 5-HT1 receptor agonists as they are known, which include sumatriptan (ImitrexÂ®), rizatriptan (MaxaltÂ®), zolmitriptan (ZomigÂ®), almotriptan (AxertÂ®), naratriptan (AmergeÂ®), eletriptan (RelpaxÂ®) and frovatriptan (FrovaÂ®).
IPSCIO Record ID: 26033
The potency and selectivity of lasmiditan make it suited to definitively test in migraine headache therapy.
Lasmiditan is an oral tablet for the acute treatment of migraine headaches in adults. In the Phase 2b clinical trial of lasmiditan, the primary endpoint. This was headache relief with statistical significance along with freedom from the associated symptoms of nausea, sensitivity to sound and sensitivity to light. The Licensee is conducting their first Phase 3 clinical trial under a special protocol assessment, or SPA, agreement with the U.S. Food and Drug Administration, or FDA, with top-line data expected in the third quarter of 2016.
IPSCIO Record ID: 3006
TreximetÂ® is a combination of IMITREX (sumatriptan) and prescription-strength naproxen sodium (an NSAID).
IPSCIO Record ID: 203351
Licensor will grant to Licensee solely for Licensees exclusive sale and distribution for sale within the Field within the Territory a non-exclusive license under the Licensed Technology to use, make, have made, import and export Products in the Field within the Territory.
Licensor grants to Licensee an exclusive license to use the Product Trademarks and Trademarks in connection with the sale and distribution of Products in the Field within the Territory.
The Licensed Technology means the Know-How, Patents, and any Improvements. The Initial Product means an oral formulation of Product containing 500mg naproxen sodium and 16mg metoclopramide hydrochloride developed by Licensor as of the Effective Date under the Licensor Marketing Authorization Application for the Initial Indication. The Initial Indication means the acute treatment of migraine attacks with or without aura.
The Product means any presentation and/or dosage strength of a formulation combining naproxen sodium and metoclopramide hydrochloride for any indication.
MT 100 is being developed as an oral first-line therapy designed to provide effective migraine relief.
MT 100 is being developed as an oral, first-line treatment for migraine. It is a patented sequential release tablet containing naproxen sodium , which relieves pain and reduces inflammation, and metoclopramide hydrochloride , which accelerates the absorption of naproxen and relieves nausea. The results from two head-to-head studies show that MT 100 provides comparable efficacy to Imitrex (R) 50 mg, the leading prescription product for migraine worldwide, but has less risk of cardiosvascular side effects compared to Imitrex.
IPSCIO Record ID: 7298
IPSCIO Record ID: 6811
IPSCIO Record ID: 4339